Topiramate Sustained-Release Beads for Once-Daily Dosing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current topiramate formulations for epilepsy and migraine management are cumbersome due to multiple daily doses, leading to peak plasma levels that cause undesirable side effects and patient non-compliance, necessitating a formulation that reduces side effects and allows for a once-daily regimen.
Innovation Solution
A sustained release formulation of topiramate with a pre-determined release profile, combining an extended release (XR) component and an optional immediate release (IR) component, where each bead population is coated with a specific release controlling coating to achieve a continuous drug release over 24 hours, minimizing peak plasma concentrations and side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If topiramate is administered as immediate release formulation in multiple divided doses, then therapeutic efficacy is maintained, but patient compliance deteriorates and side effects increase due to peak plasma levels
Solution Approach 1:
The topiramate dosage form is segmented into multiple bead populations, each with different release characteristics. Some beads provide immediate release while others provide extended release, allowing the drug to be delivered in a controlled manner over time. This segmentation enables once-daily administration while maintaining therapeutic efficacy and reducing peak plasma levels.
Solution Approach 2:
The invention changes the release rate parameter of topiramate from rapid (immediate release) to controlled (extended release). By modifying the coating properties and bead structure, the drug release profile is altered to maintain plasma concentrations within the therapeutic range without creating peaks that cause side effects, enabling improved patient compliance with once-daily dosing.
2Reliability
If topiramate is administered as immediate release formulation in multiple divided doses, then therapeutic efficacy is maintained, but side effects worsen due to peak plasma concentrations
Solution Approach 1:
The topiramate dosage form is segmented into multiple bead populations, each with different release characteristics. Some beads provide immediate release while others provide extended release, allowing the drug to be delivered in a controlled manner over time. This segmentation enables once-daily administration while maintaining therapeutic efficacy and reducing peak plasma levels.
Solution Approach 2:
The extended release beads provide continuous drug release over an extended period, maintaining plasma concentrations within the therapeutic range. This continuous release action avoids the peaks and valleys associated with immediate release formulations, thereby reducing side effects while maintaining therapeutic efficacy throughout the dosing interval.
3Ease of operation
If topiramate is formulated for sustained release, then patient compliance improves and side effects reduce, but formulation complexity increases
Solution Approach 1:
The topiramate dosage form is segmented into multiple bead populations, each with different release characteristics. Some beads provide immediate release while others provide extended release, allowing the drug to be delivered in a controlled manner over time. This segmentation enables once-daily administration while maintaining therapeutic efficacy and reducing peak plasma levels.
Solution Approach 2:
The invention uses composite bead structures with different coating materials and properties. Each bead population is a composite of core material and release-controlling coating, allowing tailored release profiles. This composite approach enables complex release patterns to be achieved through material selection rather than complex mechanical or chemical systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The sustained release formulation enables a once-daily dosing regimen, reducing side effects such as dizziness and CNS issues, while maintaining therapeutic efficacy by maintaining plasma concentrations within the effective range with minimal fluctuations, thus improving patient compliance and safety.
Implementation Method 1
each bead population is coated with a specific release controlling coating to achieve a continuous drug release over 24 hours
Implementation Method 2
topiramate is released at a rate which results in a reduction in the frequency or severity of at least one side effect
Data Source
AI summary
Pharmaceutical compositions of topiramate for once-a-day oral administration are provided. The formulations comprise a sustained-release component and an optional immediate-release component, the compositions of which can be selectively adjusted, respectively, to release the active ingredient along a pre-determined release profile. Method of treating or preventing pathological disorders in mammalian subjects comprising the administration of the novel formulations disclosed herein is also provided.